

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response...	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Wilson Donald R. Jr.		2. Issuer Name and Ticker or Trading Symbol Aptose Biosciences Inc. [APTO]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	
(Last) (First) (Middle) 540 W. MADISON ST., SUITE 2500,		3. Date of Earliest Transaction (Month/Day/Year) 08/03/2021			
(Street) CHICAGO, IL 60661		4. If Amendment, Date Original Filed(Month/Day/Year)		6. Individual or Joint/Group Filing(Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	
(City) (State) (Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/03/2021		P		57,199	A	\$ 2.647 (1)	8,948,275	I	Through DRW Investments, LLC (2) (3)
Common Stock	08/05/2021		S		60,000	D	\$ 2.62	8,888,275	I	Through DRW Investments, LLC (3)
Common Stock								4,162	I	Through DRW Commodities, LLC (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other

Wilson Donald R. Jr. 540 W. MADISON ST., SUITE 2500 CHICAGO, IL 60661		X		
DRW Commodities, LLC 540 W. MADISON ST., SUITE 2500 CHICAGO, IL 60661		X		
DRW Holdings, LLC 540 W. MADISON ST. SUITE 2500 CHICAGO, IL 60661		X		

Signatures

/s/ Donald R. Wilson, Jr.	08/05/2021
<small>**Signature of Reporting Person</small>	<small>Date</small>

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$2.64 to \$2.65, inclusive. The

(1) Reporting Persons (as defined below) undertake to provide to Aptose Biosciences Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

This Form 4 is being filed by the undersigned Donald R. Wilson Jr. ("Wilson"), as well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons"). Wilson is the sole manager of each of DRW Investments, LLC ("DRW Investments"), DRW Commodities, LLC ("DRW Commodities")

(2) and DRW Holdings, LLC ("DRW Holdings"). DRW Holdings owns 100% of the outstanding equity of each of DRW Commodities and DRW Investments. A majority of the equity of DRW Holdings is owned, directly or indirectly, by trusts for the benefit of members of Wilson's immediate family and of which Wilson serves as trustee or investment advisor.

Each of the Reporting Persons disclaims beneficial ownership of any securities held by DRW Commodities or DRW Investments, except to the extent of his indirect

(3) pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Joint Filer Information

Name: DRW Investments, LLC, DRW Commodities, LLC and DRW Holdings, LLC
Address: 540 W. Madison St. Suite 2500
Chicago, IL 60661
Designated Filer: Donald R. Wilson, Jr.
Issuer and Ticker Symbol: Aptose Biosciences Inc. [APTO]
Date of Event Requiring Statement: August 3, 2021

The undersigned, DRW Investments, LLC, DRW Commodities, LLC and DRW Holdings, LLC are jointly filing the attached Statement of Changes in Beneficial Ownership on Form 4 with Donald R. Wilson, Jr. with respect to the beneficial ownership of securities of Aptose Biosciences Inc.

Signatures:

DRW INVESTMENTS, LLC

By: /s/ Jeffrey Levoff
Jeffrey Levoff, Authorized Signatory

DRW COMMODITIES, LLC

By: /s/ Jeffrey Levoff
Jeffrey Levoff, Authorized Signatory

DRW HOLDINGS, LLC

By: /s/ Jeffrey Levoff
Jeffrey Levoff, Authorized Signatory